Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention.
BACKGROUND: Platelet glycoprotein IIb/IIIa antagonists reduce complications following percutaneous coronary intervention (PCI). There are limited data comparing different agents. OBJECTIVE: The purpose of this study was to compare in-hospital and 30-day o
Clin Ther 2003 Jan;25(1):225-34.